CG Oncology (CGON) TD Cowen 46th Annual Health Care Conference summary

Clinical trial updates and efficacy data

• BOND-003 trial shows a 75.5% CR rate at any time and 46.4% at 12 months in over 110 patients, with 90% maintaining CR at 2 years, outperforming competitors.

• Credo demonstrates promising results as adjuvant therapy in papillary disease and is being evaluated in multiple cohorts, including BCG-naive and intermediate-risk populations.

• PIVOT-006 trial uniquely includes high-grade Ta lesions and aims for recurrence-free survival, with top-line data expected this year.

• Combination studies with gemcitabine and prior work with pembrolizumab show potential for enhanced response rates.

• Early data in BCG-naive patients show an 88% complete response rate in the optimized cohort.

Regulatory and commercialization plans

• BLA submission for high-risk indication has begun, with completion targeted for 2026 and intermediate-risk filing expected in 2027.

• Manufacturing and CMC processes are a primary focus, especially fill-finish facility validation and readiness for FDA inspection.

• Commercial launch preparations include a specialized sales and medical team, targeting a concentrated market of about 300 key accounts.

• Pricing is based on dose intensity, with 30 doses over 3 years for high-risk and 14 doses over 1 year for intermediate-risk, aligning with current reimbursement models.

• Market opportunity is considered significant, with multi-billion dollar potential across indications, but penetration and persistence on therapy will determine realized value.

Competitive positioning and strategic insights

• Credo’s durability of response and safety profile are highlighted as key differentiators, especially compared to competitors like Keytruda and TAR-200.

• Launch strategy incorporates learnings from recent market entrants, focusing on prescriber behavior, access, and formulary adoption timelines.

• The product is positioned as a first-choice therapy for BCG-unresponsive disease, with a two-year lead in the adjuvant setting over other branded products.

• Upcoming catalysts include additional data readouts from ongoing trials and further guidance on regulatory timelines.

• The team leverages a strong track record in bladder cancer and is actively expanding commercial infrastructure.